[go: up one dir, main page]

HUP9802926A2 - Apolipoprotein A-I új variánsai - Google Patents

Apolipoprotein A-I új variánsai

Info

Publication number
HUP9802926A2
HUP9802926A2 HU9802926A HUP9802926A HUP9802926A2 HU P9802926 A2 HUP9802926 A2 HU P9802926A2 HU 9802926 A HU9802926 A HU 9802926A HU P9802926 A HUP9802926 A HU P9802926A HU P9802926 A2 HUP9802926 A2 HU P9802926A2
Authority
HU
Hungary
Prior art keywords
apolipoprotein
novel variants
variants
höman
apölipöprötein
Prior art date
Application number
HU9802926A
Other languages
English (en)
Inventor
Gerd Assmann
Patrick Benoit
Eric Bruckert
Patrice Denefle
Nicolas Duverger
Jean-Charles Fruchart
Harald Funke
Gérald Luc
Gérard Turpin
Original Assignee
Institut Pasteur De Lille
Rhone-Poulenc Rorer S.A.
Université Pierre et Marie Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur De Lille, Rhone-Poulenc Rorer S.A., Université Pierre et Marie Curie filed Critical Institut Pasteur De Lille
Publication of HUP9802926A2 publication Critical patent/HUP9802926A2/hu
Publication of HUP9802926A3 publication Critical patent/HUP9802926A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány a hűmán apőlipőprőtein A-I variánsaira vőnatkőzik, amelyeka 151. helyzetben ciszteint tartalmaznak, a megfelelő nűkleinsavakra,és az azőkat tartalmazó hőrdőzókra. A találmány tárgya az ezeket azelemeket tartalmazó gyógyszerkészítmények és azők alkalmazása is,nevezetesen a génterápiában. ŕ
HU9802926A 1995-05-22 1996-05-20 Novel variants of apolipoprotein a-i HUP9802926A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9506061A FR2734568B1 (fr) 1995-05-22 1995-05-22 Nouveaux variants de l'apolipoproteine

Publications (2)

Publication Number Publication Date
HUP9802926A2 true HUP9802926A2 (hu) 1999-03-29
HUP9802926A3 HUP9802926A3 (en) 2001-08-28

Family

ID=9479241

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802926A HUP9802926A3 (en) 1995-05-22 1996-05-20 Novel variants of apolipoprotein a-i

Country Status (16)

Country Link
EP (1) EP0827538A1 (hu)
JP (1) JPH11505712A (hu)
KR (1) KR19990021828A (hu)
AU (1) AU717202B2 (hu)
BR (1) BR9608813A (hu)
CA (1) CA2218759A1 (hu)
CZ (1) CZ291376B6 (hu)
FR (1) FR2734568B1 (hu)
HU (1) HUP9802926A3 (hu)
IL (1) IL118336A0 (hu)
MX (1) MX9708727A (hu)
NO (1) NO975367L (hu)
SK (1) SK156397A3 (hu)
TW (1) TW434260B (hu)
WO (1) WO1996037608A1 (hu)
ZA (1) ZA964097B (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
MXPA02008954A (es) * 2000-03-13 2003-02-12 Amgen Inc Regulacion por apolipoproteina a-1 (apo-a-1) de se°alizacion de celula t.
EP1335938B1 (en) 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein construct
NZ532217A (en) 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
AU2003239489A1 (en) 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
US7824709B2 (en) 2003-02-14 2010-11-02 Children's Hospital And Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
WO2005097206A2 (en) 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US20060030525A1 (en) * 2004-07-23 2006-02-09 Xencor, Inc. Apolipoprotein A-I derivatives with altered immunogenicity
KR100725642B1 (ko) * 2006-01-20 2007-06-07 충남대학교산학협력단 저밀도 지단백질에 대해 항산화성을 갖는 펩타이드
EP2026829B1 (en) 2006-06-01 2013-01-09 Institut de Cardiologie de Montréal Compound for use in the treatment of valvular stenosis
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
CN102239260B (zh) * 2008-10-03 2017-04-12 库尔纳公司 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
WO2010093918A1 (en) 2009-02-16 2010-08-19 Cerenis Therapeutics Sa Apolipoprotein a-i mimics
JP6219170B2 (ja) 2011-02-07 2017-10-25 セレニス セラピューティクス ホールディング エスアー リポタンパク質複合体ならびにその製造および使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
FR2734568A1 (fr) 1996-11-29
JPH11505712A (ja) 1999-05-25
IL118336A0 (en) 1996-09-12
TW434260B (en) 2001-05-16
CA2218759A1 (fr) 1996-11-28
KR19990021828A (ko) 1999-03-25
ZA964097B (en) 1996-12-06
NO975367D0 (no) 1997-11-21
SK156397A3 (en) 1998-07-08
EP0827538A1 (fr) 1998-03-11
AU5904896A (en) 1996-12-11
MX9708727A (es) 1997-12-31
CZ367197A3 (cs) 1998-03-18
FR2734568B1 (fr) 1997-06-20
HUP9802926A3 (en) 2001-08-28
AU717202B2 (en) 2000-03-23
NO975367L (no) 1997-11-21
BR9608813A (pt) 1999-02-17
WO1996037608A1 (fr) 1996-11-28
CZ291376B6 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
HUP9802926A2 (hu) Apolipoprotein A-I új variánsai
EP0847757A4 (en) A MEDICINE THAT CONTAINS THE HGF GENE
DE69426904D1 (de) Phosphonat-Nukleotid Ester-Derivate
DZ1759A1 (fr) Produits pharmaceutiques à base d'acide nucleique.
ATE141946T1 (de) Hiv-2-virusvarianten
FI950887L (fi) MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt
LU88559A1 (fr) Sels de peptides comprenant des polyesters à terminaison carboxy
CY1108537T1 (el) Ιμιδαζοκουινολινες υποκατεστημενες με αμιδιο
DE122005000024I1 (de) Darifenacin enthaltende Pharmazeutische Zubereitungen.
EP0612848A3 (fr) Gène associé à l'hypersensibilité.
DE69324826D1 (de) Gegen Papillomaviren wirksame 2',5'-OLIGOADENYLAT-2',3'-CYCLOPHOSPHATE und 2',5'-OLIGOADENYLATE
DK0825857T3 (da) Anvendelse af gabapentin og derivater deraf til behandling af mani og bipolær lidelse
FR2694296B1 (fr) Peptides inhibant l'activité des protéines ras, préparation et utilisation.
HUP9800635A2 (hu) In vivo exogén transzfekcióra és expresszióra használható gyógyászati kombináció
ATE211765T1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
FR2651505B1 (fr) Fragments d'acides nucleiques derives d'un genome de mycobacterie appropriee, leurs applications dans le diagnostic des infections a mycobacteries et plasmides contenant lesdits fragments.
DE59812317D1 (de) "Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron"
EP0670897A4 (en) INHIBITION OF THE ras GENE USING NON-CODING OLIGONUCLEOTIDES.
TR199600583A2 (tr) Farmasötik aktiviteye sahip -amino asitlerin tolere edilebilirliginin arttirilmasi.
DE69807030D1 (de) Detektion von Neisseria Gonorrhoeae mittels Amplifizierung und Detektion der entsprechenden Nukleinsäuren
IT8819791A0 (it) Peptidi ad attivita' farmaceutica.
HUP9901346A2 (hu) Deltap62 polipeptid és variánsai, ezeket kódoló nukleinsav-szekvenciák és felhasználásuk
NO178763C (no) Fremgangsmåte for fremstilling av racemisk og optisk aktiv 1,2,3,4-tetrahydroisochinolin-3-karboksylsyre samt mellomprodukter derav
DE69325695D1 (de) Protein und Gen des Glutamatrezeptors
WO1999051735A3 (de) Mapkap kinase 2-hemmer und ihre verwendung für die anti-inflammatorische therapie